Accelerating Discovery 2009-2010 Progress Report

Featuring a Special Report on Our Advance on Washington Table of Contents The Prostate Cancer Foundation (PCF) is a foundation without borders.

Founder/CEO Letter 1 Our advocacy for increased government and private support for The Promise of Personalized prostate cancer research programs has helped build a global research Cures 3 enterprise of nearly $10 billion and made PCF a respected source of Creativity & Innovation for Cures 6 KNOWLEDGE, INTEGRITY and HOPE for more than 16 million men and Reaching Patients & Families 9 their families who are currently afflicted with the disease. Special Report: PCF’s 2010 Advance on Washington 10 PCF is accelerating the most promising research and discovery of A Special Thank You 14 better treatments and cures for prostate cancer. Since 1993, PCF has Events for Cures 21 raised more than $415 million and funded more than 1,500 research Appeal for Support 22 projects at nearly 200 institutions in 12 countries. Donation Opportunities 23 Financial Statements 24 PCF researchers are fast-forwarding breakthroughs in prostate cancer Partners for Progress 28 research that will enable us to achieve our vision for a world where no Board of Directors & Leadership Team 29 man suffers or dies from this disease.

About the Cover: A Rosetta Stone for Prostate Cancer PCF-supported researchers at the University of Michigan identified 24 types (clonotypes) of prostate cancer; 23 are caused by specific gene fusions (erroneous pairings of genetic codes) and one is initiated by an overexpression of a gene called SPINK1. Like a Rosetta Stone, this historic decoding of prostate cancer 5-Year Revenue History 2009 Spending opens a new world of understanding $Millions Per Dollar and will accelerate discovery of better early diagnostics and $0.73 treatments. It permits differentiation 40 $37.2 Prostate Cancer Research Mission between non-life-threatening and $35.4 35 $33.2 aggressive forms of prostate cancer $31.1 $0.57 $0.16 and enables clinicians to match Research Grants Public Education $28.2 & Programs & Advocacy patients to treatments that are most 30 Support effective for their particular clonotype. The discovery represents 25 a pivotal moment in PCF’s mission to cure more and overtreat less, 20 bringing an end to death and suffering from prostate cancer. 15

$0.17 About the Graphs: 10 Fundraising PCF’s expertise enables us to maintain revenue levels despite 5 economic fluctuations. Agility allows us to fund crucial research 0 $0.10 immediately and ensure progress. 2005 2006 2007 2008 2009 Administration ACCELERATING DISCOVERY

Dear Friends,

The exciting news from the front lines of cancer we can better decode cancer markers and distinguish research is that the pace of scientific progress has between life-threatening tumors and indolent accelerated, delivering more results in prostate varieties that do not require aggressive treatments. cancer research in the past 12 months than in the More great news is the approval of two new drugs for past decade. This is translating into more advances prostate cancer in 2010, Provenge® (immunotherapy), and hope for the more than 16 million men and their and Cabazitaxel (chemotherapy), and the pending loved ones affected by prostate cancer around the approvals of Denosumab (fracture prevention) and world. In the field of medical research against deadly Abiraterone (hormone therapy). diseases, prostate cancer stands out as an area delivering promising results for better and earlier Provenge is the first immunotherapy shown to be diagnosis so we can cure more and overtreat less. effective in extending the lives of men with advanced prostate cancer. It is an important proof of concept Our ability to reach this historic point in cancer demonstrating that we can harness the power of research is built on the generosity of the more than the body’s own immune system to fight cancers—a 170,000 donors who have helped us raise over $415 scientific concept that PCF began funding more than million for game-changing research since 1993. 10 years ago. PCF is pursuing additional research so we can better understand how immunotherapy We reached several important milestones in 2010. works and why it is effective for some patients and The discovery of 24 types of prostate cancer by PCF- not for others. funded researchers at the University of Michigan is a breakthrough finding. As a Rosetta Stone for prostate Cabazitaxel is an advance in secondary chemotherapy cancer research, this important advance provides for advanced prostate cancer. This new agent is the key to one day being able to prescribe highly effective in men who become resistant to Docetaxel, personalized treatment plans. The Michigan team’s a long-preferred chemotherapy. Furthermore, gene fusion research identifies specific targets, so Denosumab, a drug used to maintain bone strength

2009-2010 progress report 1 and prevent fractures in men undergoing androgen Creativity Awards and allowed us to realize our goal deprivation therapy (ADT), represents an important of supporting more than 50 Young Investigators by advance for improved survivorship. the close of 2010. These new research awards are in addition to our support of 15 existing multi-million Following successful completion of Phase III clinical dollar, multi-year Challenge Award commitments trials, Abiraterone is in the final evaluation and and sponsorship of the Prostate Cancer Clinical decision process at the Federal Drug Administration Trials Consortium (PCCTC) that is partnered with the (FDA). It blocks the production of testosterone, Department of Defense. Since 2005, the PCCTC has the fuel for prostate cancer progression, and is enrolled more than 2,400 patients in clinical trials targeted for use in men who have become resistant that deliver innovative new treatments to patients. to current androgen deprivation drugs such as By the second half of 2010, 12 new Phase I and Phase Lupron. It is already being cleared by the FDA for II clinical trials were in the pipeline and seven new use on a case-by-case basis for patients who have protocols were activated by the Consortium. no other treatment options. Abiraterone was initially discovered at the Institute of Cancer Research in PCF advocates for more research in addition to London. PCF-funded investigators participated in its funding it. In September 2010, PCF moved its 17th development and researched how it works. Annual Scientific Retreat to Washington, D.C. as part of a major Advance on Washington. In conjunction A fifth potential new drug on the horizon for patients with three other prostate cancer organizations, this is Ipilimumab, another promising immunotherapy effort provided a week of scientific, advocacy, and agent. It is currently pending approval at the FDA government outreach meetings and events that for melanoma patients and is in Phase III trials for stimulated much-needed media awareness and prostate cancer patients with metastatic hormone- government attention in Congress and at the White refractory disease. PCF funded much of the House. We are pleased to include a special report on fundamental science and early clinical investigations these activities. for this promising treatment. With your continued support, we will further our In addition to five new drug treatments, the stem progress. We will find an end to prostate cancer. “cell of origin” for human prostate cancer was Thank you for helping us make it happen. identified. For decades, scientists believed that prostate cancer stem cells originated in luminal With sincere appreciation, cells that line the top of the tiny ducts of the prostate. However, this year, UCLA researchers supported by PCF showed that basal cells, found at the base of the prostate ducts, are the source for prostate cancer. This finding directs researchers to the cancer’s source and will enable them to better understand the primary mechanisms for prostate cancer and identify new treatment targets.

We urgently need to build on this progress, which produces a host of new opportunities to turn lab discoveries into new and more effective medicines. Mike Milken Jonathan W. Simons, MD Founder and Chairman President and In 2009, PCF recorded its third-highest year for Chief Executive Officer contributions despite the global recession. The David H. Koch Chair $33.2 million you donated helped to fund 10 new

2 2009-2010 progress report the promise of Personalized cures A Reality Within Reach

In 2010, prostate cancer research achieved an historic number of milestones. The progress made in the past year accelerates fundamental discoveries that will translate into cures. We are closer than ever to realizing our vision of delivering personalized cures for every patient who is diagnosed.

A “barcode” approach to prostate cancer treatment will include a variety of data points specific to each individual patient.

Decoding Cancer through Gene Fusions gene fusions. The team, led by Michael Rosenfeld, MD, has developed a process that can artificially create PCF-funded researchers at the University of Michigan, these fusions in normal prostate cells in the lab to led by Arul Chinnaiyan, MD, PhD, made a landmark screen for compounds that prevent cancer. discovery by identifying 24 types of prostate cancer. Of these, 23 are indicated by distinct gene fusions, and Memorial Sloan-Kettering Cancer Center scientists, one is defined by an enzyme called SPINK1. Many of funded by PCF, identified a genomic signature of these gene fusions could disclose the Achilles’ heel RNA and DNA codes for men who may not need of a distinct set of prostate cancers and markers for surgery or radiation and those who most likely need disease aggressiveness. Investigations to determine aggressive treatment. With these signatures, doctors the function of each gene fusion will be essential to can potentially talk to their patients about whether or delivering new medicines designed to target specific not they need additional therapy following surgery. types of prostate cancer. The purpose of this continuing research is to integrate genomic information into a “barcode” for each patient University of California, San Diego researchers are that would match them with personalized, predictive building on the Michigan discovery by investigating and optimal treatments. the molecular mechanisms that mutate into recurrent

2009-2010 progress report 3 Discovering the Stem Cell of For the first time in oncology, activating a patient’s Prostate Cancer immune system prolonged the survival of a patient with an advanced solid tumor. This new cell-based therapy is proof of principle that the immune system can be harnessed against advanced disease, even after cancer has emerged and spread. Today, PCF-supported scientists are at work on the next generation of vaccines and antibodies that re-task the immune system to unleash tumor-fighting cells.

Advancing Beyond the PSA Debate with Liquid Biopsies

Daniel Haber, MD, PhD, a PCF Challenge Award recipient, and his team at Massachusetts General Hospital is speeding the delivery of a liquid biopsy for prostate cancer patients. The newest device

Basal cells do not express PSA (prostate-specific antigen), but features a 10 to 1000 times greater detection rate for have the capacity to generate malignant glands (seen above in a single circulating tumor cell (CTC) in a drop of blood. reddish-brown) expressing PSA. (Image courtesy of UCLA) This scalable device increases the probability of a CTC to interact and adhere to the walls of the capture Owen Witte, MD, at the University of California, device. This data will enable doctors to tell how Los Angeles, made a seminal discovery that was aggressive the cancer is and how fast it is growing. published in the journal Science this year. The paper’s authors identified prostate basal stem cells (found at the base of the prostate ducts) as the Fighting Androgen Deprivation- prostate cancer cell of origin, a surprise to the Resistant Cancers field that speculated only epithelial cells (that The androgen receptor is one of the central drivers line the prostate ducts) could be the cell of origin. behind prostate cancer cell growth. Advances in This finding elevates the level of stem cell knowledge blocking androgen receptor signaling are urgently for the research community and will aid in the needed for patients whose initial response to discovery of new targeted medicines. They will be traditional androgen-blocking drugs is followed by a aimed at exterminating the elusive prostate cancer relapse from resistant cells. Thanks to $14.6 million stem cell, a therapy-resistant cell capable of in new seed funding from PCF, we now have two oral regenerating an entire tumor. androgen receptor-blocking antagonists that can actually put patients back into remission: Abiraterone Harnessing the Power of the (Johnson & Johnson) and MDV3100 (Medivation, Inc.). Immune System In Phase III clinical trials of Abiraterone, a PCF- Since 1993, PCF has funded innovative prostate supported team of clinical scientists in London, New cancer research aimed at harnessing the immune York and San Francisco, reported a significant survival system to fight prostate cancer. In fact, PCF funded advantage in androgen deprivation-resistant prostate early dendritic cell based research, including the first cancer. Abiraterone is an inhibitor of the enzyme research ever conducted on Provenge (sipuleucel-T). CYP17 which is critical for the synthesis of intra- In April 2010, the FDA approved Provenge as the first tumoral androgens. MDV3100, another novel anti- immunotherapy for metastatic prostate cancer. androgen, is in Phase III trials under the leadership

4 2009-2010 progress report is testing new androgen inhibitors and discovering new resistance mechanisms with the goal of further improving patient treatment.

Improving Survivorship

Challenge Award recipients Matthew Smith, MD, PhD, of Massachusetts General Hospital, Michael Pollak, MD, of McGill University, and Stephen Freedland, MD, of Duke University are focused on understanding and treating the side effects of

Dr. Peter Nelson at Fred Hutchinson Cancer Research Center at androgen deprivation therapy (ADT). One significant the University of Washington is collaborating with PCF-funded outcome was the successful Phase III clinical trial scientists and investigating Abiraterone resistance in patients. of Denosumab that reported a reduction in bone fractures caused by ADT. An additional effect of of a PCF-supported team at Memorial Sloan- this therapy is the onset of metabolic syndrome, a Kettering Cancer Center. Biomarkers for patient Type II diabetes-like disorder. Epidemiology studies selection and rapid determination of outcomes are show reduced incidence of prostate cancer in men embedded in both of these studies. For example, CTC taking Metformin for diabetes. A clinical trial of measurements are being tested as early indicators Metformin in patients receiving ADT, to prevent of remissions. New imaging techniques are being metabolic syndrome, will commence soon. qualified as earlier biomarkers of treatment success. As a result of the rapid acceleration of discovery in Collaboration between Challenge Award recipients prostate cancer research and greater participation in Steven Balk, MD, PhD, at Beth Israel Deaconess our clinical trials, we envision a day when every man Medical Center, Peter Nelson, MD, at Fred Hutchinson will have access to better diagnostics that will enable Cancer Research Center, and investigators at physicians to prescribe treatments matched perfectly Harvard, studied the inevitable development to their specific cancer type. of Abiraterone resistance. Additional androgen metabolism inhibitors are being tested in combination with Abiraterone to eliminate residual androgen and disease recurrence. Furthermore, Trevor Penning, PhD, at the University of Pennsylvania discovered five new compounds that inhibit androgen synthesis differently than Abiraterone. His team

2009-2010 progress report 5 CREATIVITY & INNOVATION FOR CURES Much of the progress that has been made in our efforts to end prostate cancer is the direct result of PCF’s commitment to funding innovative ideas and high-risk yet high- reward projects that are typically left unfunded by more traditional, government- supported programs.

Cory Abate-Shen, PhD (2009) Columbia University Medical Center The Gordon Becker Creativity Award

Gustavo Ayala, MD (2010) Baylor College of Medicine

Brendan Curti, MD (2010) Providence Portland Medical Center

Adam Dicker, MD, PhD, Karen Knudsen, PhD (2009) Kimmel Cancer Center, Thomas Jefferson University The Charlie Wilson Creativity Award

Jennifer Doll, PhD (2010) NorthShore University HealthSystem Research Institute The more we learn about prostate cancer, its origins and mechanisms, the more complex the remaining Charles Drake, MD, PhD (2010) challenges become. PCF’s Creativity Awards The Sidney Kimmel Comprehensive support game-changing ideas, accelerating the Cancer Center at Johns Hopkins world’s most promising research. PCF also invests The Evensen Family Creativity Award in Young Investigators to build human capital and support a robust research enterprise. These grants Shelton Earp, MD (2009) are designed to attract the world’s brightest young University of North Carolina scientific minds and encourage them to dedicate The Michael Vinecki Creativity Award their research careers to solving the problem of Barbara Graves, PhD (2009) prostate cancer. University of Utah Our commitment to creativity and innovation David Heber, MD, PhD (2009) engages intellectual power and resources to find University of California, Los Angeles solutions from entirely new concepts and advances in immunotherapy, biomarkers like gene fusions and Towia Libermann, PhD, Alan Rigby, PhD (2009) circulating tumor cells, and new targeted medicines. Beth Israel Deaconess Medical Center Harvard Medical School

2009 and 2010 Creativity Awards James Marshall, PhD (2010) Roswell Park Cancer Institute Twenty-two new Creativity Awards were selected from 457 applications representing more than 100 David Nanus, MD (2009) institutions worldwide. Historically, 70 percent of Weill Cornell Medical College these awards have leveraged additional multi-year The Dan Fogelberg Creativity Award funding from government, biotech and pharma. These new grants represent a total new Nora Navone, MD, PhD (2010) commitment of $4.6 million. The University of Texas MD Anderson Cancer Center

6 2009-2010 progress report William Oh, MD (2010) Brett S. Carver, MD Mount Sinai School of Medicine Memorial Sloan-Kettering Cancer Center The David H. Koch Young Investigator Award Pier Paolo Pandolfi, MD, PhD (2009) Beth Israel Deaconess Medical Center Robert Den, MD Harvard Medical School Kimmel Cancer Center, Thomas Jefferson University The Ben Franklin Young Investigator Award Renata Pasqualini, PhD (2010) The University of Texas MD Anderson Cancer Center Felix Feng, MD University of Michigan Kenneth Pienta, MD (2010) The Republic of Tea Young Investigator Award University of Michigan David S. Finley, MD Matthew Rettig, MD (2010) University of California, Los Angeles University of California, Los Angeles The Lynda & Stewart Resnick Young Investigator Award

Matthew Smith, MD, PhD (2010) Isla Garraway, MD, PhD Massachusetts General Hospital University of California, Los Angeles Muneesh Tewari, MD, PhD (2009) The Winter Vinecki Young Investigator Award, Fred Hutchinson Cancer Research Center sponsored by Lori Milken and University of Washington Hans Hammers, MD, PhD The Arnie’s Army Creativity Award Johns Hopkins University Medical School John F. Ward, MD (2009) The William Bikoff Young Investigator Award The University of Texas MD Anderson Cancer Center Daniel Hamstra, MD, PhD Scott Williams, MD (2010) University of Michigan Peter MacCallum Cancer Centre, Australia The Charles Dolan & Mark Walter Young Investigator Award

2010 Young Investigator Awards Julia Hayes, MD Dana-Farber Cancer Institute With 27 new Young Investigators added to 23 from The Ressler-Gertz Family Foundation 2008, PCF is now funding 50 projects led by young Young Investigator Award and innovative researchers whose backgrounds include computer science, molecular biology, Hannelore Heemers, PhD pharmacology, radiation oncology, medical oncology Roswell Park Cancer Institute and endocrinology. Recipients receive three years The Heritage Medical Research Institute of funding to test transformational research Young Investigator Award questions for prostate cancer patients. The 2010 Andrew C. Hsieh, MD Young Investigator Awards represent a $6.1 million University of California, San Francisco investment in the global cancer research community. Through the generosity of an anonymous donor

Himisha Beltran, MD Joshua Lang, MD, MS Weill Cornell Medical College University of Wisconsin The LeFrak Family Young Investigator Award Carbone Cancer Center Justine Bruce, MD The Dendreon Corporation Young Investigator Award University of Wisconsin Stanley Liauw, MD Carbone Cancer Center University of Chicago In Honor of Our Soldiers and the Department of The Brookdale Foundation Young Investigator Award Defense Congressionally Directed Medical Research Program for Prostate Cancer

2009-2010 progress report 7 Christopher Maher, PhD Philip Saylor, MD University of Michigan Massachusetts General Hospital The Stewart Rahr Young Investigator Award The Stewart Rahr Young Investigator Award

Ram S. Mani, PhD Jennifer Schutzman, MD, PhD University of Michigan University of California, San Francisco The Stewart Rahr Young Investigator Award The Richard N. Merkin, MD Young Investigator Award

Neil Martin, MD, MPH Jay Shendure, MD, PhD Dana-Farber Cancer Institute and University of Washington Brigham and Women’s Hospital The Lowell Milken Young Investigator Award The David Epstein Young Investigator Award Neha Vapiwala, MD Kenneth May, MD, PhD University of Pennsylvania Dana-Farber Cancer Institute The Emilio Bassini Young Investigator Award The David Epstein Young Investigator Award

Prior to the start of our 17th Annual Scientific Retreat, PCF Young Investigators, mentored by PCF-supported scientists, spent a day identifying new challenges in our scientific agenda and innovative approaches that may deliver research solutions and cures.

Nicholas Mitsiades, MD, PhD Amina Zoubeidi, MSc, PhD Baylor College of Medicine University of British Columbia Vancouver Prostate Centre Akash Patnaik, MD, PhD The Durden Foundation Young Investigator Award Beth Israel Deaconess Medical Center The Stewart Rahr Young Investigator Award Amado Zurita, MD The University of Texas MD Anderson Cancer Center Edwin Posadas, MD The David & Judy Fleischer Young Investigator Award University of Chicago The Stewart Rahr Young Investigator Award For complete information on PCF’s 2009 and 2010 grant recipients and their projects, and to learn more about PCF research initiatives and strategies, scan this QR code with your smart phone, or go to: www.pcf.org/research.

8 2009-2010 progress report REACHING PATIENTS & FAMILIES PCF is committed to providing men and their families the best information available on the current best practices for treatment and the latest research findings. We fulfill this task by leveraging the benefits of online and social media, in addition to traditional methods of communication.

A New Web Presence with pcf.org awareness program for pcf.org on widely-read WebMD® and a new prostate cancer blog, In 2009, PCF’s communications team undertook an www.mynewyorkminute.org, are also helping to extensive upgrade of pcf.org. Using input collected introduce patients and their caregivers to PCF, its from surveys of patients, caregivers, researchers mission and information resources. and other medical professionals, a new website was launched in April 2010. The new site features: Reaching a Disproportionately-Affected • Enhanced user interface and navigation Population of Men

• Daily news feeds from Reuters and HealthDay Understanding that African-American men are 60 • Patient percent more likely to be diagnosed with prostate information cancer and 2.4 times more likely to die from it, PCF provided identified an urgent need to better reach this group of according to men with the important message of early detection patient and treatment. In 2009, PCF teamed with Grammy- disease nominated R&B artist and survivor Charlie Wilson status and the Black Barbershop Health Outreach Program • Rich video (BBHOP). Through his concert tours and media content coverage, Wilson has delivered this important health • Expanded message to more than three million American men survivor and and their families. PCF also provided BBHOP with a researcher stories Communications Grant to support its 50 City Tour, A marketing program, designed to provide urologists bringing information on prostate cancer, diabetes with patient information materials and drive new and hypertension to inner-city African-American visitors to the website, was launched in September, communities. To support these efforts, PCF produced 2010. The first wave of materials was mailed to a special brochure, Prostate Cancer: Straight Talk for practitioners in the New York and Los Angeles African-American Men and Their Families, available at metropolitan areas. This program will be www.pcf.org/guides. monitored and assessed for further implementation in the coming year.

The Power of Social Networking

In 2009, PCF launched several social media initiatives. Within 12 months, the number of PCF Facebook friends grew by more than 1,000 percent to over 8,000. Since January 2010, PCF has attracted more than 1,500 Twitter followers. These tools deliver breaking news and information to PCF followers in a highly-visible and cost-effective manner. A pilot

2009-2010 progress report 9 SPECIAL REPORT PCF’s 2010 Advance on Washington

To increase awareness and promote government engagement, PCF moved the 17th Annual Scientific Retreat from Lake Tahoe to Washington, D.C. in coordination and partnership with other leading prostate cancer organizations.

PCF mobilized the meeting and spearheaded a nation’s leaders. During the press conference, PCF cooperative effort with ZERO—The Project to End issued a Five-Point Call to Action for ending prostate Prostate Cancer, the cancer that was Prostate Health endorsed by 14 U.S. Education Network prostate cancer (PHEN) and the Black organizations. Barbershop Health PCF representatives Outreach Program were featured guest (BBHOP). The vision speakers at ZERO’s was to create a critical Advocacy Summit, the mass of events and African-American meetings during Prostate Cancer September, National Disparities Meeting Prostate Cancer sponsored by PHEN, Awareness month. and at the The Advance on Congressional Black Washington was a Caucus Meeting. The highly visible and BBHOP, with integrated program of sponsorship from PCF, media events and concluded the week by meetings focused on conducting special prostate cancer informational events research, discovery, and health screenings advocacy, healthcare for prostate cancer, disparities and overall hypertension and awareness. diabetes at 16 inner- city barbershops in Washington, D.C. and Baltimore. With more than 1,000 scientists, specialists, advocates and patients converging on our nation’s The 17th Annual Scientific Retreat was the largest to capital, PCF and the three partnering organizations date and received high marks for its content and were able to share program speakers and hold a joint context. Prostate cancer researchers and patients press conference. This effectively advanced our will benefit from the Advance on Washington for message for increased government support to our months to come.

10 2009-2010 progress report PCF’s Five-Point Call to Action

1. Increase the NCI’s $5 billion annual budget to accelerate basic and treatment sciences research for human prostate cancer from $294 million to a transparent $400 million.

2. Increase the appropriation for the Congressionally Directed Medical Research Program for Prostate Cancer at the Department of Defense to $120 million from $80 million.

3. Establish an Office on Men’s Health (OMH) in In the U.S. alone, more than $1 billion is spent each the Department of Health and Human Services equivalent to the Office on Women’s Health (OWH), year on overtreating men who are diagnosed with established in 1991. non-life-threatening varieties of prostate cancer, while more than 32,000 will die from the aggressive 4. Create a Prostate Cancer Scientific Advisory types of this cancer in 2010. By 2015, the number of Board for the Office of the Chief Scientist at the new annual cases is predicted to rise beyond 300,000 FDA to accelerate real-time sharing of the latest from 218,000 in 2010, making prostate cancer the research data and accelerate movement of new number one men’s health crisis in America. medicines to patients.

With recent progress, prostate cancer is at an historic 5. Create human capital by launching more careers turning point. We believe we can soon reach our goal of the best and brightest scientists in the U.S. to of curing more and overtreating less, ending death solve the prostate cancer problem. and suffering from this disease while returning During the Advance week, Senate Bill S.3775—The billions of dollars to the American economy. However, Prostate Cancer Act of 2010—was introduced by we cannot let up on government and private Senator Jon Tester from Montana (pictured below). It investment for a cure. calls for greater coordination and inter-agency The Five-Point Call to Action issued to our nation’s research collaboration, and greater reach to rural leaders is designed to free us from the burden of patients. At the close of September, House Bill H.R. prostate cancer. The Call to Action is endorsed by 6389, supporting prostate cancer research and PCF and 13 other prostate cancer organizations. education, was introduced by Representative Edolphus “Ed” Towns from New York. • American Urological Association • The AUA Foundation • Black Barbershop Health Outreach Program • Malecare Prostate Cancer Support • Men’s Health Network • National Alliance of State Prostate Cancer Coalitions • Prostate Cancer International • Prostate Conditions Education Council • Prostate Health Education Network • The Prostate Net • US TOO International • Women Against Prostate Cancer • ZERO—The Project to End Prostate Cancer

2009-2010 progress report 11 Clockwise from top left: Jean Fogelberg speaks at PCF’s Survivors Breakfast • Tom Farrington of the Prostate Health Education Network and Dr. Stanley Frencher of the Black Barbershop Health Outreach Program answer questions at the Advance on Washington joint press conference • Dr. William Nelson, Senator John Kerry (D-MA) and PCF Chairman Mike Milken at the Congressional Reception on Capitol Hill • Dan Zenka, PCF VP of Communications, opens the Survivors Breakfast with PCF Young Investigators • Dr. Charles Sawyers shares his research at PCF’s Scientific Retreat • Movember founder

12 2009-2010 progress report Adam Garone addresses attendees at PCF’s Retreat • Mike Milken and Senator Jeff Sessions (R-AL) at the Congressional Reception • PCF donor Stewart Rahr discusses the latest in scientific advances with PCF Young Investigators • PCF Young Investigators collaborate on innovative research prior to the opening of the Scientific Retreat • U.S. Speaker of the House, Nancy Pelosi and Mike Milken speak to members of the press on Capitol Hill • PCF President and CEO, Dr. Jonathan Simons speaks at the press conference • Reverend Rosey Grier, PCF director, and Senator Jeff Sessions meet on Capitol Hill

2009-2010 progress report 13 A special thank you The Prostate Cancer Foundation would like to thank everyone who has supported us during the past seventeen years. We gratefully acknowledge the following individuals, foundations, corporations and others who have given at least $5,000 since our founding.

Founders ($50,000,000+) Eric D. Becker Herb and Natalie Kohler Cendant Corporation Milken Family Foundation Bill and Ann Bresnan Foundation, Inc. Robert A. Kotick John and Jennifer Chalsty The Bunker Foundation Kovler Family Foundation Max C. Chapman, Jr. Founders’ Circle Ronald W. Burkle Lamkin Corporation Chicago White Sox ($2,000,000 to $49,999,999) Gary and Tina Lowenthal Jerry and Adrianne Cohen Anonymous (4) Winston H. Chen, Ph.D. F. W. McCarthy Foundation James H. Coleman Leon and Debra Black Stephen and Chantal Cloobeck Medical Research Agencies of Robert D. Collins Fund Bristol-Myers Squibb Company Lawrence J. Ellison America Concern Foundation Jamie B. Coulter R. Christian B. Evensen Richard Mejasich The Carole & Robert Daly The Charles Evans Foundation Sue Gin MidOcean Partners Charitable Foundation David H. and Julia Koch D. Wayne and Anne Gittinger Jay and Elaine Moorin, Alain Neil P. DeFeo Thomas H. Lee and Ann Tenenbaum Golfers Against Cancer and Iris Schreiber, and Ronald M. DeFeo Carl Lindner The Greenspun Family Foundation ProQuest Investments Thomas and Gun Denhart Lowell Milken Guggenheim Investment Management, LLC Joseph Neubauer James and Kristin Dolan Michael and Lori Milken Richard and Deborah Justice Joel M. Pashcow Dunwoody Senior Men’s Golf The News Corporation Foundation Peter Karmanos, Jr. Allen and Madeleine Paulson Association Stewart and Lynda Resnick C. Michael and Elizabeth Kojaian Sandra and Lawrence Post Jeremy D. Eden Safeway, Inc. Richard S. and Karen LeFrak Family Foundation Lee and Daniele Einsidler Sanofi-Aventis Charitable Foundation Leonard and Louise Riggio Don Engel M. Shanken, Chairman/ M. Shanken Jeffrey A. Marcus Marc J. and Carolyn Rowan Ernst & Young LLP Communications, Inc. Joy and Jerry Monkarsh Gene and Marianne Salmon Robert S. Evans Stephen and Elaine Wynn Family Foundation The John F. Scarpa Foundation Faith, Love, Hope, Win Foundation Leadership Circle Gordon E. Moore Melvin and Bren Simon Charitable William F. Farley ($1,000,000 to $1,999,999) Bruce and Jeannie Nordstrom Foundation No.1 M. Anthony and Anne Fisher Anonymous (5) Novartis Pharmaceuticals Joseph and Diane Steinberg 1992 Sidney E. Frank Charitable Trust Abbott Laboratories Corporation Friendship Foundation, Inc. Paul and Elle Stephens Baume & Mercier Co. Stewart and Carol Rahr Richard S. Fuld, Jr. Sterling Equities Conde Nast Publications, Inc. Lewis and Peg Ranieri The David Geffen Foundation Robert & Jane Toll Foundation Charles F. Dolan Brian and Patricia Reynolds Richard and Phyllis Gelb Warren and Jale Trepp William L. Edwards William A. Richardson Genentech Foundation Clyde T. Turner Edward P. Evans Foundation Richard V. and Ellen Sandler, Esq. Eric and Anne Gleacher Vadasz Family Foundation Andrew S. Grove Mickey and Karen Shapiro Robert B. and Pamela Goergen Varian Medical Systems, Inc. Kern Family Fund Lester and Sue Smith Foundation Thomas and Holly Gores Robert and Angela Voss Sidney Kimmel Edward M. Snider Greenbriar Golf Association The Wagner Family Foundation Rush Limbaugh Sportsgrants, Inc. Orland S. Greene Dennis and Phyllis Washington The Lincy Foundation Stuart Subotnick Wayne and Janet Gretzky Foundation The Honorable Earle I. and Carol Mack Yahoo! The Sam and Sarah Grossinger Gary and Karen Winnick Major League Baseball Charities, Inc. Foundation Patrons Martin and Audrey Gruss Charles N. Mathewson Foundation ($250,000 to $499,999) Partners The Craig and Susan McCaw Bayer Corporation ($100,000 to $249,999) Richard B. Handler Foundation Brian and Kathleen Bean Anonymous (1) Joseph W. Harch Richard N. Merkin, MD Charles and Michelle Becker William and Donna Acquavella J. Ira and Nicki Harris Movember, Inc. Marc R. Benioff The G. Chris Andersen Thomas O. Hicks Family Foundation James W. Newman Bloomberg LP Hilton Hotels Corporation Phillip and Nancy Anschutz Kerry Packer The Eli and Edythe Broad Foundation Leo Hindery, Jr. Ambassador George L. Argyros, Sr. Nelson and Claudia Peltz James and Patricia Cayne Thomas and Virginia A. Hughes Arnie’s Army Battles Prostate Cancer Ronald O. Perelman L. John Doerr Hugo Boss Fashions, Inc. Atlanta Hawks PGA Tour Charities, Inc The Durden Foundation, Inc. Jon and Karen Huntsman The Lynn Aymar Family Foundation Cliff and Debbie Robbins David and Marsha Ederer Carl and Gail Icahn Chris and Tory Bagdasarian Julian H. Robertson, Jr. David J. Epstein Mel and Terry Karmazin Charles F. Baird, Jr. William A. Schwartz Ralph and Cynthia Finerman David Karpol Robert Baldwin Terry and Jane Semel David and Judith Fleischer Solomon Kerzner Ron and Judy Baron David E. and Beth Kobliner Shaw Gen-Probe Incorporated Michael and Jena King The Cecile and Fred Bartman Thomas Spiegel The Gillette Company W. C. Klintworth Foundation Lawrence J. and Joyce Stupski Howard Gittis Knowledge Universe Braman Family Foundation Tarnopol Family Foundation, Inc. Phillip and Lyn Goldstein Laborers’ International Union Gary S. Broad of North America Wade F.B. Thompson Harkins Charitable Gift Fund Charitable Foundation The Brookdale Foundation The Leeds Family Foundation Heinz North America Ted and Dani Virtue John and Barbara Burns W. Howard and Mary Lester Steven and Tomisue Hilbert Martin and Pamela Wygod August A. Busch, IV Robert Levin The R.D. and Joan Dale Hubbard California State Council of Laborers Stanley and Barbara Zax Foundation Solomon and Rosie Lew Callaway Golf Sales Company Ray and Ghada Irani Peter B. Lewis Benefactors Ely R. Callaway William and Phyllis Mack ($500,000 to $999,999) Peter W. Janssen Wayne Calloway Margaritaville Holdings, LLC Anonymous (4) Michael Jordan CAO International, Inc. Peter and Leni May Joseph and Annette Allen Kissick Family Foundation Dick and Lisa Cashin Bruce R. and Jolene M. McCaw Fund Robert K. Barth Charles G. Koch

14 2009-2010 progress report George A. Mealey Michael and Marlene Aufrecht Internet Real Estate Group, LLC Harvey L. Silbert, Esq. Keith Meister Facundo L. Bacardi Jim Beam Brands Co. Jeffrey and Helaine Silverstein Robert A. Meister Mr. & Mrs. Robert Baker William P. and Dorian S. Jordan Herb Simon Avram Miller Family Foundation Foundation, Inc. William E. and Tonia Donnelley Simon S. Leslie and Barbara Misrock Robert Bales David G. Kabiller, CFA Paul and Celia Sirotkin Kenneth and Julie Moelis Roger Barnett Joseph H. Kanter Foundation Stuart M. Sloan Moore Family Foundation Frank and Kathy Baxter Matthew Kaplan Jeff P. Smith John and Rebecca Moores Erin and Douglas Becker Bruce E. Karatz Southern California District Marc and Jane Nathanson Samuel Belzberg John Kelley Council of Laborers Linden Nelson Marshall Bennett Melvyn N. Klein Saul P. Steinberg George and Sandra Norcross Ken Berg David and Janet Kline Fund James Stern John and Sally Nordstrom Martin and Phyllis Berman The Kobrand Foundation Sternlicht Family Foundation OSI Pharmaceuticals Robert and Catherine Beyer Fred Kolber Louis B. Susman Palermo Ravich Family Foundation Frank and Carol Biondi, Jr. Timothy Koogle Allan Tessler Rick Pitino The Stanley & Joyce Black Dewanto Kurniawan William H. Tilley Bruce I. Raben Family Foundation Emeril Lagasse Time Inc. Mark Redmond Annual Jim & Diane Blair Charitable Benjamin V. and Linda Lambert Pier Luigi Tolaini Golf Tournament Foundation Kenneth and Linda Lay Joe and Alice Torre Sumner and Paula Redstone Dan Blumenthal Robert E. Linton Jeanette Trepp The Republic of Tea Boston Red Sox Ira A. Lipman Trimaran Capital Partners Allan V. Rose Jerry Brassfield Los Angeles Angels of Anaheim Marc and Mindy Utay Lew Rothman Shann Brassfield Los Angeles Lakers Clark Van Nostrand The Rachel and Lewis Rudin Gresham T. Brebach, Jr. Macquarie Bank Limited Charles J. Wagner Family Foundation, Inc. Steven A. Burd Laurence and Karen Mandelbaum Mark R. Walter Larry W. Ruvo Frank Caufield Bernard Marcus Alice Walton Haim and Cheryl Saban Century Golf Partners Management Michael Marek Cheng Ching Wang San Francisco Giants Ray and Patti Chambers Stanley and Pamela Maron Casey and Laura Wasserman Stephen L. Schwartz Alfred and Kathryn Checchi Joseph and Anne McCann Jerry and Jane Weintraub Stephen A. Schwarzman Marshall and Maureen Cogan John E. McCaw Gary and Nina Wexler Brett T. Setzer Robert and Beverly Cohen Richard McKenzie, Jr. David Yandry David and Janelle Shaffer Family Foundation Jerome Meislin Don Yannias J. Gary and O.J. Shansby Foundation Countrywide Credit Industries Herman and Susan Merinoff Silent Partners Inc. Howard Cox Barry Meyer Friends Shoes for Crews, LLC Dendreon Corporation Millennium Pharmaceuticals, Inc. ($25,000 to $49,999) Anonymous (1) Jeffrey and Lisa Silverman Detroit Tigers Michael Minikes A Charity Challenge Skull Creek Development Michael D. Dingman Edward J. Minskoff Don Ackerman Eric and Susan Smidt Ty and Fran Durekas Morongo Band of Mission Indians Neale M. Albert, Esq. Don Soffer Robert and Tricia Earl Nat. Amer. Rights Fund Norman E. Alexander David M. Solomon Bruce Eichner Robert E. Morrow Allchin Foundation Martin & Toni Sosnoff Foundation BlackRock Financial Management Angelo and Phyllis Mozilo Judd Apatow Alex G. Spanos William B. Finneran Ken Nees Arby’s The John R. & Inge P. Stafford First Data Western Union Foundation Neiman Marcus Direct Frank J. Arcella Foundation Paul M. Fleming NetJets Aviation, Inc. Matthew Arcella Joe Fred Starr Forester Family Foundation Aviv Nevo Roland E. Arnall Avy and Marcie Stein Theodore J. Forstmann New York Mets Foundation, Inc. AstraZeneca Ernest E. Stempel Freeport-McMoRan Foundation L. Mark Newman Family Foundation Jude T. Barbera, MD The Stern Family Foundation Michael Frey Phil R. North David W. Bash, PhD and Roger and Susan Stone Jerry Friedman Ruth Ornest Judy Oliver-Bash, PhD Swing for the Cure Carlos Fuente, Jr. Jon Otto Candice Beaumont Marty Tenenbaum The Gaba Family Foundation The Palin Family Foundation, Inc. Arthur Becker and Vera Wang Laurence and Billie Tisch Gantcher Family Philanthropic Fund Jim Pattison Robert A. Belfer Tom and Diane Tuft Jeffrey D. Garguilo and Valerie Boyd Ethan Penner Art H. Bilger Barbara Tyson Arthur and Linda Gelb The Picower Foundation Les and Sheri Biller Van Van Auken Jay Geldmacher Chris Prezioso Bobby Blair Ira Walker Russell and Zina Geyser Pritzker Foundation Charles X. Block Jay L. and Linda G. Wallberg Global Fitness Holdings, LLC Alan Quasha Bluefish Concierge, Inc. Raul and Vicki Walters Henry and Arline Gluck Martin and Patricia Raynes Salvatore and Alison Bommarito Wasserman, Comden, Casselman Stanley P. Gold Tony Ressler and Jamie Gertz Bonita Bay Community & Pearson, LLP Jeremy P. Goldberg Richard S. Ressler David Booth Will K. Weinstein Richard and Marcia Goldberg Meshulam Riklis Tony Borhani Thomas and Emily Weisel Bennett and Meg Goodman The Riordan Foundation Boston Red Sox Foundation John F. Welch, Jr. John R. and Kiendl Dauphinot George R. Roberts Denis A. Bovin Herbert A. Wertheim Gordon Fund The Rose Foundation The Braka Philanthropic Foundation Gregory White Stephen Gordon Andrew M. Rosenfield Harry M. Brittenham, Esq. Jim and Kim Williams John and Kathleen Gorman E. John and Pat Rosenwald Coco Brown Zapolin Transactional Ventures, Inc. GPC Biotech Steven and Daryl Roth Thomas and Jo Anne Bruno Sam Zell Greenbriar at Whittingham Eric Rothfeld John M. Bryan Selig Zises John A. Griffin Peter H. Rothschild Brian P. Burns Movado Group, Inc. Alvin and Marilyn Rush Associates Arthur Byrnes William and Susan Gross Mike Ryan ($50,000 to $99,999) Andrew S. Clare Allen Grubman Ronald S. Saks Anonymous (5) Brian and Denise Cobb Norb Guziewicz Ronald Salkow AJA Charitable Fund Gregory and Monica Coleman Clay W. Hamlin, III The Mara and Ricky Sandler Robert and Jodi Allardice David and Courtney Corleto Alan and Vivien Hassenfeld Foundation Edward C. Allred Country Club of Roswell Sam Herzberg Richard J. Schmeelk Altadis USA, Inc. Lester and Renee Crown Houston Golf Association Allen B. Schwartz Kenneth Ambrecht Edgar and Elissa Cullman Roy W. Howard Thomas J. Shannon, Jr. Matthew Arcella Ian M. Cumming James Hudson Howard P. Shore Eric J. Aronson Michael Huffington Robert and Kelly Day Arthur J. Gallagher & Co. Mace and Jan Siegel

2009-2010 progress report 15 Celine Dion Foundation Jerry Lee, Newton Running Company Spencer Stokes Dennis Block Mark Donnelly Ken Leese Stricklin Account of Fidelity Charitable Bloomberg Financial Markets Co. Michael Dougherty Steve Lehman Gift Fund Bernt O. Bodal Efficiency Enterprises John S. Levy Burt and Mary Sugarman Burton Borman Harvey P. Eisen Linder Charitable Remainder Unitrust Jim Tarlton Albert R. Boscov Lewis M. Eisenberg Joseph Rob Link Douglas P. Teitelbaum G. Michael Boswell Lawrence R. Elins Lords Valley Country Club, Inc. William Thompson Reggie Bowerman Endo Pharmaceuticals Vincent Lorio James Tisch Steve Braverman The Entertainment Industry Los Angeles Dodgers Bruce E. and Robbi S. Toll Foundation Bernard and Judy Briskin Foundation Joe Lumarda Varhegyi Foundation Broad Street Productions Thomas J. Fazio Susan E. Lynch Peter Vegso Brooklyn Hospital Center Ferolito, Vultaggio & Sons Gene E. Lynn Michael and Laura Venerable Harry J. Brown Foundation Cary Fields Donald and Hilda Lytton Linda J. Wachner Gloria S. Browning Steve Fink David S. Mack Samuel Waksal Bryanston Group, Inc. Alex Fisher Fredric Mack Elmer Ward Bulk Truck and Transport Service, Inc. Peter E. Fleming, Jr. Harvey Mackay Scobie D. Ward Kurt W. Butenhoff Todd Follmer Stewart Manheim Michael and Jill Weinstein Bernie F. Butler Theo and Constance Folz Howard and Nancy Marks Stephen and Phyllis West Michael Butler Lionel Frais Robert and Joan Masterson Henry Wilf The Capital Group Companies John R. Frank Harold Matzner Christopher and Kristine Williams Charitable Foundation Keith Frankel Robert and Marilyn May Alexander J. Witherill Cardean Learning Jim Freer Keith W. McCaw Douglas Wood Cardinals Care Robert Fremont Michael McKeever Rick Wooley Michael Caridi Josh S. Friedman Dennis Mehiel Don Zacharia Ronald G. Carley Steven Friedman Merck and Co., Inc. Liam Carlos Supporters Paul R. Garcia Harold M. Messmer, Jr. Anthony and Jamie Carr Philip H. Geier, Jr. ($10,000 to $24,999) Johnny Carson Theodore N. Miller Anonymous (1) GNC Donald and Nancy Carter Minnesota Twins David and Kay Aaker Stephen and Mindy Geppi Edwin P. Carter Molecular Insight Paul Abecassis Charles and Vivian Gillespie Pharmaceuticals, Inc. Marx L. Cazenave, II Abraham Kaplan Foundation The Honorable Rudolph W. Giuliani Jim Mooney Tom Celani S. Daniel Abraham GivingCapital, LLC James F. Moore Cell Genesys, Inc. Abramson Family Foundation, Inc. Bruce Goldstein Mark E. Mortimer Centocor, Inc. Joseph P. Adams, Jr. Eric Goldstein Stuart W. Moselman Irwin Chafetz Sheldon Adelson Michael Goldstein John Nickoll Charity Folks, Inc. Larry Alleto Litto Gomez T. D. O’Connell Linda Chen Alpha Tau Omega Edward and Cheryl Gordon Chris K. Olander Peter Chernin Bruce and Elvin Ambler Maureen V. Gorman Pierre and Pam Omidyar Allen and Jill Chozen Lee W. Ang Fredric Gould Ozaukee Country Club Chubb Federal Insurance Company Michael F. Armstrong John P. Gould Dean E. Palin Citigroup Michael F. Ashby Alan C. Greenberg Larry R. Palmer The Clark Charitable Foundation Martha A. Atherton Haarlow Family Charitable Foundation Matthew Pisoni H. Lawrence Clark Atlanta Braves Foundation, Inc. Kenneth B. and Carolyn Hamlet William J. Polvino The Clinton Family Foundation Mark and Debbie Attanasio John J. Hannan John and Laura Pomerantz Steven Clinton Jerry Auerbach Reed and Nan Harman Portland Bolt & Manufacturing Coca-Cola Co. Autism Speaks, Inc. William Hartnett Steve Posner Harold K. Cohen Abraham Azoulay Hastings Capital Group, LLC Post Advisory Group Mitchell H. Cohen Baby Togs John R. and Lauren Haynie, Jr. Anthony & Jeanne Pritzker Jim and Marcia Colbert Dan Baldwin Ralph and Kay Hemingway Family Foundation Commerce Bank, North, N.A. Jeffrey and Pamela Balton John and Susan Hess Royce G. Pulliam Connecticut Baseball Charitable Martin and Dorothy Bandier Samuel J. Heyman Mark Quigley Foundation Jeffrey C. and Lori Barbakow Kenneth and Janet Himmel Ed W. Rabin Jimmy and Patti Connors Sol Barer HLT Prostate Cancer Fund Richard E. Rainwater Nancy and James Cook F. Harlan Batrus H. S. and Diane Hoffman Ramblewood Country Club The David and Sheila Cornstein Michael J. Batza, Jr. Charlie J. Horky Joseph Reece Foundation William P. Beatson, Jr. David S. Howe and Charlene Wang Bob Roberts Corte Bella Women’s Golf Association Richard I. Beattie Michael R. Howland Bill R. Roberts Jack B. Corwin Warren Beatty Charles and Barbara Hurwitz Neal I. Rodin Ken Cory Gary S. Becker The Iacocca Foundation Richard and Barbara Rosenberg Robert H. Cosgriff Michael Becker IRI Golf Management, LP Stan and Patti Rosenfeld Terry Cosgrove Mitch Becker Jack’s Broken Open Round Hill Country Club Cotton Creek Men’s Golf Allen J. Beeber Steve and Ellen Jackson Andrew Ruotolo Association, Inc. Alan T. Beimfohr Herb W. Jacobs Barry L. Rupp The Gerald and Daphna Cramer William J. Bell Family Foundation Stanley R. Jaffe Peter M. Sacerdote Foundation Lee and Susan Benton Credit Suisse First Boston Christopher M. Jeffries David Sambol Eric L. Berg Corporation Joseph Drown Foundation Richard and Margaret Santulli Jeff Berg Alberto Cribiore John Kahrhoff Memorial Golf John H. Schnatter Anthony Bergamo, Esq. Robert and Mary Ann Cross Gerald Katell Irving Schneider Elliott H. Berger Cuba Club The Fritz and Adelaide Kauffman Michael and Paola Schulhof Daniel G. Bergstein Chip Cushman Foundation, Inc. David and Fela Shapell David Berkoski Theodore Cutler Stephen and Marina Kaufman William Shaw The Judy and Howard Berkowitz Cytogen Corporation KB Home David and Lynn Silfen Foundation Dabney/Resnick Imperial J. Christopher Kennedy Mark J. Simon Allen J. Bernstein Dalio Family Foundation, Inc. Michael Klein Fred L. Smith Fred B. Bialek John Daly Henry R. Kravis Smithburg Family Foundation William Bikoff Darling Family Fund Bill Lane, Jr. Irwin and Lorri Spiegel The Black Family Charitable J. Morton Davis Jeffrey & Nancy Lane Foundation, Inc. St. Louis Cardinals Foundation, Inc. Marvin and Barbara Davis Gerrity Lansing Fred and Sharon Stein Harvey Blau Roger J. Davis Bennett and Jerri Lebow Steinberg Family Fund, Inc.

16 2009-2010 progress report Michel De Beaumont R. Anthony Goldman The Joseph and Ida Foundation Inc. Les G. McCraw, Jr. Delcal Enterprises, Inc. Russell D. Goldsmith Mitch Julis Jeffrey and Ashley McDermott Joseph J. Dempsey The Golfworks The Kandell Fund John and Constance McGillicuddy Cosmo DeNicola The Gordon Family Foundation Kansas City Royals MCI WorldCom Foundation Donald J. Deutsch Edward and Cheryl Gordon Harold Sanford Kant, Esq. Thomas J. McKearn Deutsche Bank Berry Gordy, Jr. Scott G. Kasen Kara McKinley Terry and Marilyn Diamond Abraham D. Gosman Peter M. Kash Laureston and Barbara McLellan Dietz & Watson Foundation Laurence Graff Howard and Susan Kaskel J. P. McManus Richard DiMeola Mark Grant George Kaufman James A. McRae Dinan Family Foundation Madison and Susan Graves David and Silvana Kay Medco Containment Co. Don King Productions, Inc. George D. Grayson Joshua and Joia Kazam Todd Meister Donaldson, Lufkin & Jenrette George & Reva Graziadio Foundation Dean C. Kehler Prakash Melwani Carl Doumani Steven and Dorothea Green Gregory F. Kiernan Arnon Milchan Dow Electronics Gary and Sandra Grimes Brian King Lee and Sylvie Millstein Milton H. Dresner Foundation, Inc. Grizzard Family Foundation, Inc. Michael G. King, Jr. Milwaukee Brewers David H. Dreyfuss Julie Groshens Lila Kingsley Larry A. Mizel Joseph J. Dvorak, Jr. Michael S. Gross Kirkland & Ellis Foundation MLB.com Alvin Dworman The Marion and Louis Grossman Joel Kirschbaum Robert Michael Mondavi Eastdil Realty, Inc. Foundation Calvin Klein Charles K. Monfort Charles Edelstein H.J. Heinz Company James W. Klein Eugene Monkarsh Stephen Einhorn Blair R. Haarlow John Kliger David Moore David F. Eisner Roger S. Haber Michael and Patricia Klowden Jacques J. Moore Niko Elmaleh Thomas R. Hagadone and Pam Miller KML Golf, LLC Pete Moore Elmwood Country Club Kerry and Kelly Hagen Emerson and Peggy Knowles William S. Morris, III The Engelberg Foundation David and Leslie Hahn Harold and Shirley Kobliner Jerry Moss Roger A. Enrico Brian L. Halla Jeff Koffman Wayne Mueller Mike Ensign James A. Harmon Roger and Lorraine Kotch Donald R. Mullen Gamma Enterprises, LLC Richard J. Harrington KPMG, LLC Peter Mullin The Daniel J. Epstein Fund of the Joshua J. and Marjorie Harris Jules B. Kroll Bill Mundell Jewish Community Foundation Mel Harris A. B. Krongard Hilary Musser Jeff Epstein William B. Harrison, Jr. Mark Kurland Miles Nadal Evergreen Foundation Richard C. Hartnack Herbert and Edyth Kurz Naples Drive for the Cure Eugene and Sallyann Fama Albert and Irene Hartog Lachman Family Foundation The Nash Family Foundation Jonathan D. Farkas Home Box Office LA-CO Industries, Inc. Menasche M. Nass Federated Department Stores Richard J. Heckmann L’Acquisition Corporation David Nazarian Foundation Andrew L. Heiskell Martin and Sheila Lasky NBS Diamonds, Inc. Jeffrey P. Feingold Bruce Heller Latham & Watkins Marty Nealon Brad Felenstein Jane Heller Leonard and Evelyn Lauder Rooney Nelson Robert M. Fell The Helping Hands Sales, Inc. William P. Lauder Blake Lee Neubauer James and Alise Ferency Jerry Hennessy Steve Lawrence and Eydie Gorme New England Financial Mike Ferry Lawrence Herbert Norman Lear New Jersey Basketball, LLC The Diane and Elliot Feuerstein Heritage Operating, LP Lederman Family Foundation Wayne and Kathleen Newton Fund of the Jewish Community Leon and Norman Hess Don and Rita Lee NFL Charities Foundation Andrew R. Heyer Schwartz, Kales Accountancy Corp. Perry Nisen Mark Finerman Steven Higger Stephen R. Leibowitz Northern California District Gerald B. Finneran Highlands United Methodist Men Alfred and Norma Lerner Council of Laborers Jerome and Anne Fisher Rick Hill Julius and Miriam Lesner Novacea, Inc. Larry and Kathleen Fisher Joni Hirsch Blackman Frederick N. Levinger Marlene Nusbaum Lester and Gwen Fisher The Armin & Esther Hirsch Foundation Frances and Jack Levy Foundation Oakland Athletics Richard Fisher Douglas Hirsch and Holly Ander Richard Levy Cindy K. Olson Dawn N. Fitzpatrick Hitching Post Motels Loida N. Lewis Paul, Weiss, Rifkind, Wharton Joseph Flom Beth Hollfelder Robert Lienau & Garrison, LLP Florida Marlins Butch Holmes Lights Out for Cancer Peter Busch Orthwein Steven T. Florio Jane Holzer Mrs. Arthur Liman Gregory J. and Mary V. Pacelli Jean Fogelberg Homayoun Homampour Steven Lipman Chuck Palombini Lynn Forester Steven and Cathy Hooper Michael D. London Marvin Parsons Michael G. Foster, Jr. Houston Astros Lord Abbett & Co. LLC Alan Patricof William C. Foster D. E. Brice Howe David B. Lowry Norman J. Pattiz FOXSports.com HSK Funding Rufus and Patricia Lumry David Pecker Fred Hutchinson Cancer Helmut Huber Robert G. Lusk Gerry Pencer Research Center Gene Humphrey LZR Sports, LLC Arthur Penn Paul Fribourg Michael Hyatt Jerome D. Mack Pensions 2000 Friedman Family Foundation Royce Imhoff Richard Mack Leonard C. Perham Larry H. Friend International Financiers, Inc. Macy’s Phillips-Van Heusen Foundation, Inc. Peter Fudge Invemed Associates, LLC John Magliocco Phoenix Home Life Mutual Jeffrey Furman Ironman Motivations Peter A. Magowan Insurance Company Frederick and Peggy Furth Nathan P. Jacobs Mandalay Resort Group Elizabeth Pinsonault Ronald H. Galowich Sheldon Jacobs Alan and Barbara Mandelbaum Albert and Jeanine Pirro Brian Gamache Ron Jacoby Mandelbaum Foundation Michael A. Pitino Michael and Lynn Garvey Robert M. Jaffe Mel Mannion Mack Pogue Arie Genger Leonard R. Jaskol Stephen J. Marcus Carl and Eloise Pohlad David H. Glaser Family Foundation The JCT Foundation Mariners Care Guilford and Diane Glazer The Poses Family Foundation Michael and Linda Jesselson Morris Mark Alan and Marlene Gleicher Maury Povich and Connie Chung Johnson Bank Howard and Stacy Marks Seth Glickenhaus Michael J. Price Clark A. Johnson Nancy Marks Colin Goddard, Ph.D. William L. Price Allen N. Jones Maverick Capital Foundation Bradley and Sunny Goldberg Wayne Prim, Jr. Ellis B. Jones Kenneth Mazik Michael A. Goldberg Jay Pritzker Glenn R. Jones Larry Mazzola Andy Goldfarb Prometheus International, Inc. Wayne D. Jorgenson Michael and Kristy McChesney

2009-2010 progress report 17 Quiksilver Foundation Eugene Silverman Shirlene A. Wainer The Baupost Group, LLC Harvey and Pauline Radler Jay B. Silverman William and Claudia Walters David I. Bavar Sheri and Marc Rapaport Fund of the Thomas M. Simms Kenneth Wang Beacon Hill Country Club Jewish Community Foundation Ted Simpkins William and Sharon Ward Lee Beattie Mr. and Mrs. Joseph Rascoff Sirens Society Tom Watkins Jack M. Beaven Bruce Ratner Sanford Sirulnick Scott Watt Fred Bedard Michael Ratner John and Cindy Sites Armond Waxman Bradley Bell Randolph and Lindsey Read Charles B. Slack Robert F. Weis John Bendheim John S. Reed Alan B. Slifka Melvyn I. Weiss The Frances & Benjamin Benenson Richard and Marget Reneberg Lynn Smiledge Morris Weissman Foundation W. Brent and Brenda Rice John F. Smith, Jr. Whittemore Family Foundation Walt L. Bent Denise Rich Matthew and Tracy Smith Ralph and Wendy Whitworth Philip J. Bergan Robin Richards Orin Smith Arthur Wiener Martin S. Berger James S. Riepe Family Foundation Snyder Weiner Weltchek & Vogelstein Andrew Wise Stephen Berger Richard A. Rigg Marilyn Sobel Fred Wolf Richard Berkowitz Harold W. Ripps Bruce Sokoloff Douglas J. Wood Leonard H. Bernheim, Jr. Richard K. Robbins Bob Solomon C. Tal Wooten, Jr. Anthony J. Bettencourt Brian L. Roberts Warren J. Spector Leah Wurzberger William C. Bevins Kenn Roberts Allison Speer Young Presidents Organization Les Bider Ralph J. Roberts Aaron and Candy Spelling Los Angeles Chapter Elliot and Susan Black Thomas and Mary Alice Roberts Jerry Speyer Gerard Yvernault Marc Blackman W. Scott and Karen Robertson The Jerry and Emily Spiegel Louis G. Zachary, Jr. Robert S. Blank James D. Robinson, III Family Foundation Harriet Zaretsky Michael and Nina Blechman Rodney Strong Vineyards Lawrence Spira Jeffrey Dunston Zients Tim Blixseth Gerald Ronson Sports Licensed Division of the Adidas Ron Zimmerman James A. Block Allison Rosen Group, LLC Roy Zuckerberg Ron Boeddeker Fredric D. Rosen Starkey Sports Consulting, LLC Robert A. Zummo Franklin Otis Booth, Jr. Paul and Catherine Rosenberger The Starr Foundation Sergio Zyman Kurt T. Borowsky Betsy Ross Joseph Stein Richard Boughner Byron Roth Jeffrey Steiner Contributors Boustead Family Foundation, Inc. ($5,000 to $9,999) James Rothstein Irving Stenn, Jr. Larry Bowman Anonymous (1) Michel Roux Karl Sternbaum Thomas S. Bowman 12th Man Foundation Michael D. Rudd Gary Stoneburner Leonard Boxer Robert J. Abt James Russell Michael Strauss Thomas and Janine Braman The Adams Family Charitable Fund Kenneth and Dina Russell Lawrence Sheldon Stroll Breast-Prostate Cancer Benefit Addison Reserve Edward B. Rust, Jr. Melanie Sturm at SWCC The Adler Family Foundation, Inc. Stephen Ruzow and Donna Karan Marianne Sufrin Thomas Breitling Advance Shared Services Center Steve Sanak Sanford and Charna Sugar Stephen M. Brett AIECA of America, Inc. Raymond and Helen Sandler Sunbelt Beverage Company, LLC Pete Briger AIM Management Group Richard Sandor Sunrise Rotary Foundation Pam Brill Alvin R. Albe, Jr. Michael Sandorffy Katharyn Swintek Nancy Brinker Ellis J. Alden Sylvan Schefler Tag Associates, LLC Gary Briskman Richard L. Alderson Andrew Scheinman Roberta R. Tanenbaum F. James Brock R. Jack and Beulah Alexander David Schneider Tanger Factory Outlet Centers, Inc. Edward Brodsky Donald and June Alford Raymond D. Schoenbaum Edward Taran Jeffrey P. Brown Allied Beverage Group, LLC Lewis M. Schott Jeremiah and Nonie Tarr Richard A. Brown Arthur G. Altschul, Jr. Ian Schrager Stanley G. Tate Sam Brown Ellsworth C. Alvord, III Joan and Paul S. Schreiber Fredricka Taubitz Christopher H. Browne Richard W. Alvord Philanthropic Fund of the Ian Ross Taylor Richard C. Browne American Endowment Foundation Jewish Communal Fund Robert Taylor C. Kenneth Brumit Ameripoint Foundation David K. Schulhof Teleflora, LLC Marc R. Brutten John Angelo Schultz Family Foundation Anthony Terlato Deborah L. Burger, Inc. Terry Anthony Marvin H. Schur Terravita Golf Club, Inc. Alan A. Burgess Kenneth and Diane Aretsky Charles and Helen Schwab Texas Propane Gas Association William and Elizabeth Burroughs Tom Armstrong Alan D. Schwartz T. F. Trust Jack Burstein Arris Interactive, LLC Barry K. Schwartz Family Foundation Charles and Adele Thurnher Richard Byrd Phillip Asherian Ted Schwartz Steve Tino Richard J. Byrne Michael Ashkin Charles Scott Andrew H. and Ann Tisch Roger and Mary Campbell Sherrell Aston Russell Scott, Jr. Daniel and Bonnie Tisch Cancer Awareness Gold at Heritage Victor K. Atkins Tony Scotti Steven H. Tishman Eagle Bend David and Elisangela Aufrecht Sebastiani Vineyards, Inc. Dennis A. Tito Canoe Brook Golf Shop Ralph H. and Susan August Security Life Inc. Group John T. Toland Phil Caputo Margaret and Edward Augustine Henry Seiden Richard P. Torykian, Sr. James A. Cardelli Aureon Laboratories, Inc. Ivan G. Seidenberg Jesse I. Treu CARE Rick G. Avare Martin Selig Prabhakar Tripuraneni William M. Carson Bacardi Limited Mike Shad The Trump Organization S. Ward and Roxanne Casscells, III Roland and Beverly Bacci Michael Shapiro Tudor Investment Corporation Frank L. Cassidy, Jr. David and Michelle Bach Richard and Phyllis Sharlin Robb & Elizabeth Tyler Matthew J. Celozzi, II Shearman & Sterling Foundation, Inc. Baltimore Orioles Chajet Family Foundation Howard Shecter Valquip Corporation Scott P. Barasch Michael J. Charles Mark Shenkman Karen van Nouhuys Paul and Norma Barash Sophie Chen Robert D. Shipp Mari and Ash Vasan Alexander E. Barkas and Bernd Chorengel Lynda Wijcik Boaz Shonfeld Mary T. Venable Clarium Capital Management, LLC Janice Barney Walter Shorenstein Stephen and Laurie Vogel Greg Clark John R. Barney Pam Shriver Fund of the Baltimore The Vons Companies Charitable John H. Claster The Barrack Foundation Community Foundation Foundation, Inc. Cleveland Cavaliers Tyler Barth Stan Shuster Rosemary Vrablic CMA Consulting Services Charles T. Bauer Stanley J. Sidel Don Vultaggio Bert Cohen Ted Baum Sanford C. Sigoloff Benjamin A. Wade Joseph M. Cohen

18 2009-2010 progress report Karen B. Cohen Foundation, Inc. Albert Fried, Jr. James Husband John L. Loeb, Jr. Richard D. Cohen Joel Friedland George Hutchinson Florian J. Lombardi Foundation The Betsy and Alan Cohn Robert and Ann Fromer Arthur I. Indursky Shumer Lonoff Foundation, Inc. Front Line Management Group, Inc. Institute for Health & Productivity Bob Lorsch Victor A. Cohn Roy Furman Management Douglas and Nancy Lowe Mary and Robert Colgan Tom W. Gamel Integrated Health Campus Lyncar Enterprises, Inc. Collington Transportation Golf Outing Howard L. and Judie Ganek Hale S. Irwin Tom Wallace Lyons William S. Comanor Philanthropic Fund Steve Iverson Gordon Maahs Kerby and Judith Confer Lloyd Garver Jeremy Jacobs Harry Macklowe Connecticut MSBL Lucio Dallla and Marta Gasperina Max Javit James and Gail Maclin Michelle A. Connelly Frank Gehry Jefferson University John Magnier Elaine Terner Cooper Alan Gelband Gordon W. Jenkins Anthony J. Magro John Cooper, Jr. Gelfand, Rennert & Feldman, LLP Charles Jennings Brian A. Maki Stephen A. Cooper Georgetown Tobacco & Pipe Daryl L. Jesperson Idelisse Malave Peter Coors Stores, Inc. Jewish Federation of Judd Malkin The Copses Family Foundation S. William Gersten Greater Phoenix Shareef Malnik Corinthian Colleges, Inc. Michael F. Gilligan, Jr. JFD / MJD Golf Open George J. Maloof Fred Corrado Tom Giovanelli James and Lorene Jimmerson Susan Mandelbaum Marshall B. Coyne David Glass Alastair J. Johnston Alan and Nancy Manocherian Cresa Partners Arthur M. Goldberg The J.P. Morgan Chase Foundation Manowitz and Drillings Family Cullasaja Club, Inc. Howard Goldenson Kaiser Permanente Foundation Gregory Cuneo Steve A. Goldfarb Jay Kaiser Philip and Marcia Marcus Cunningham Security Systems Kenneth N. Goldman Peter S. Kalikow Bernard A. Marden Cushman & Wakefield David and Renee Golush Thomas J. Kalinske Ken Martin Billy Davis, Jr. Jan Goodman Adam Kalish Kim Martindale Marion J. Davis, Jr. Bradford S. Goodwin Bruce and Jeanie Kaminsky Elliott Masie Peter and Julie Dawson Richard Goodwin Walter Karabian Norman and Joanne Matthews Ed DeBartolo, Jr. Todd Goodwin Eric P. Karros Giacomo Mattoli Paul R. Del Rossi Jerome S. Gore Stanley Katz Caryn Mautner Delaware North Companies, Inc. Louis and Nancy Grasmick Stephen Katz Max Performance, LLC Jerry Della Femina Jim Grau Ivan Kaufman Thomas and Musa Mayer Dodger Dream Foundation, Inc. Jerry and Barbara Greenbaum Ronald S. Kaufman James N. McCoy Foundation Robert Dodson Charles H. Greenberg Ilan and Linda Kaufthal Richard E. McCready Foundation Fund Drexel University, College of Medicine Mark Greenhill Richard and Suzanne Kayne of the Baltimore Community Drexel University Robert W. Greenman, Jr. Gershon Kekst Foundation William E. Dreyer Bill Greer Donald H. Keltner Liam E. McGee Daniel A. Duc Dennis M. Griffin Ken Roberts Company John S. McIlwain Duch Family Fund of the Community Robert Grossman Jeff & Erica Keswin Family Foundation Don McNamara Foundation of New Jersey GSI Commerce Keys Foundation Robert J. McNulty Raymond Duncan Howard R. Gurvitch Kidz, LLC Bryan and Cynthia McWeeney Prince E. Eagilen Lynn M. Haff Jerry King Rolf Meijer-Werner Eagle Watch Ladies Golf Association John Hagestad Kirk and Kathleen Knous The Melville Foundation J. C. Earle Family Fund Hall Dickler Kent Goldstein & Burton Koffman Merrill Lynch & Co. Foundation, Inc. Walter Eberstadt Wood, LLP Eric D. Kogan Leroy Merritt Spencer F. Eccles Bryan Hallman Oswaldo Kosta The Morris and Helen Messing David B. Edelson The Hallman Foundation Robert Kraft Foundation Daniel D. Ederer Jesse Halperin Orin S. Kramer Dorothy Phillips Michaud Maurits E. Edersheim Fred Hameetman Norman D. Kurtz Charitable Trust Anders B. Eklov William and Vicki Hamilton John and Kay Kyle Dwayne Middleton Richard and Gail Elden Mark S. Handler Laborers’ International Union of David A. Miller Robert Englander Mark S. Hanson El Monte-Local 1082 Michael and Laura Miller Yan Erlikh Martin Aaron Harmon Laborers’ International Union of Honorable Robert Joseph Miller Aaron R. Eshman Gilbert W. Harrison N. America-Local 300 Sherman R. Miller, IV and Mary Linda Evangelista Lauren M. Hartman Laborers’ International Union- Sullivan Peter Evans Edward J. Hawie Local 270 The Litwin Foundation, Inc. William F. Evans Jerry and Marilyn Hayden Constance C. and Linwood A. Lacy, Jr. Thomas K. Miller Samer Farah Kenneth and Kathryn Henderson Foundation MillerCoors, LLC Andrew Farkas Thomas S. Henderson and Sally S. Fred S. Lafer Peter H. Mills John Farnsworth Henderson Foundation Robert F. Lampe, Jr. Phillip S. Mittelman Farrell Family Foundation Arthur Hershaft Robert Larner Alan Mnuchin Michael S. Fawer Michael B. Hershey Ronald Lauder Arthur and Patricia Modell Stanley M. Feingold Edward and Gaye Hewson Lynn M. Leany James J. Moglia Irving Feintech David Hicks Frank Leanza David Moore Rajiv Fernando The Hill Family Charitable Foundation Charles E. Leonard, III Raymond Moore Frank and Victoria Fertitta Roderick Hills Steve Leonard The Mr. October Foundation for Kids David Fillmore Leslie Wohlhan Himmel Warner LeRoy Morongo Band of Mission Indians Gregory Fischbach Richard Hise Margaret Lesher Morton’s Restaurant Group Siegfried and Doris Fischer Peter A. Hochfelder John and Betty Levin Judy Bardugo and Harve H. Mossawir, Jr. Richard B. Fisher Robert W. Hoke Neil Levine Paul Motenko Stephen B. Fiverson Richard Scott Hollander Dan and Stacey Levitan Charles H. Mott Dennis Flatt Mark Holowesko David Levy Joseph M. Murphy Donald Folgner Vincent Horcasitas Laurence R. Levy Alan C. Myers Robert Forbes Gerald Horowitz Edward Lewis Douglas P. Nation Sam Forman John and Sandra Horvitz David Liebowitz NBA Properties, Inc. Gayle Devers Fortune Thomas J. Howa Sio Lindner Renato Negrin David Foster Joe Howe Samuel S. Lionel Lee S. Neibart Fox Hill Country Club Harry and Elsie Huber Jeffrey and Susan Liss Craig T. Nelson Michael F. Frankel Mark Hughes The Loa Productions, Inc. Mary-Rose Nelson Franklin Country Club Wayne Huizenga The Arthur Loeb Foundation

2009-2010 progress report 19 Nestle Waters North America, Inc. Iber Rodriguez John Stark Legacy Shilom Neuman Sig Rogich Steven E. Stern Robert C. Atherton Chuck Nicolette Jeffrey Rosenthal The Stone Family Fund Joseph DeVito Niebaum-Coppola Estate Winery Beth and Peter Rosenthal Tom and Bonnie Strauss Bernie and Ralph Dunnigan James B. Nish Memorial Fund, Inc. William W. Stuart Estate of Dennis Shea Robert Noelke Stephen M. Ross Chris Stuhmer Bruce Moore Goedde Douglas and Nancy Norberg Gordon Roth Thomas R. Sturges Olin Howser Greg Norman Edward F. Rover Fred and Judith Sullivan Bruce Alan Hupfer Memorial John and Maryann Norris Royals Charities Mary M. Sullivan The Estate of Corbin Page North Atlanta National Bank Richard and Amy Ruben Suns Legacy Partners, LLC Edward M. Piluso Jonathan R. Novak Howard Rubin Dennis A. Suskind Edward F. Sulesky Estate NHSU Foundation Mariano A. Rubino Don Swirnow Obermeyer Asset Management Stephen and Cheryl Rush S. Jerome and Judith Tamkin Champions for a Cure Company Sheryl Lee Russo and Eva G. Guajaro Rica F. Tarnoff Nick Adcock James T. O’Brien Denny Ryerson Jeffrey Tarr Andrew Akiyoshi Morris Offit Thomas L. Safran Janie C. Tarter Max Andes John O’Hurley Saul and Evelyn Salka Walter D. Tearse Sal Augeri Marvin Olshan Max and Janet Salter Vincent Tese The Baggio-Millstein Wedding Shepard Osherow San Diego Padres Andrew Thomka-Gazdik Gareth Barlow Dan Otter Allan C. Sanders Chuck B. Thornton, Jr. Ray Bayat John Paffenbarger Theodore and Alison Sands The Laura Steinberg Tisch Foundation, Inc. Peter Binks Donald P. Pakosh Sandy Spring Bank Tom Tisch Erlend Bo Norm Pappas Jill and Ronald Sargent TJH Michael Cameron J. Douglas and Marian Pardee Patrick Savin Stephen G. Tolchin Damien Clark Donald J. Parmet Saybrook Tax-Exempt Advisors, LLC James E. Tolson, Jr. David S. Deschenes Charles A. Partain Randall H. Scarlett Thomas Tonko Jeff Dorman Partners Marketing Group Anthony Scavo, Jr. Eugene and Judith Toombs Scott Duxbury Rafael Pastor Al Scheid Stanley S. Trotman, Jr. Fans of Dan Fogelberg Thomas J. Patrician Schmertz Company, Inc Cecily Truett Matthew Friend E.H. Patterson Alfons J. Schmitt Mark Truitt Kimberly Fry Frances B. Paulsen David M. Schoenthal Trump Administration Blair R. Haarlow Randall Eric Paulson Marvin I. Schotland Jeffrey H. Tucker Brandon Haley Clay Pecorin Robert Schulman Tuesday’s Children Matthew J. Hoffman Elsie Pecorin Gerald M. Schuster Turner Broadcasting System, Inc. Carlo Huber David R. Pedowitz Homer R. Schwartz UBS AG S. Andrew Katz Pelican Preserve Golf Governor Arnold Schwarzenegger and Peter V. Ueberroth David Kimmel Robert F. Pence Mrs. Maria Shriver William D. Unger Emerson T. Knowles James C. Pendergast Lisa White Schweitzer Unified Grocers Scott Kolasinski The Peninsula Club Peter W. Schweitzer United Jewish Foundation of Gideon Lang-Laddie Pennsylvania Breast Cancer Coalition Spencer and Jacqueline Segura Metropolitan Detroit Ryan Link Bruno and Nichola Perillo Michael E. Seiff United Way of Greater Los Angeles Jeffrey Maddox Mark Perlbinder Richard M. Seigel Tom Unterman Brett Matik Charles Persico Sellers Publishing, Inc. Michael J. Urfirer Ray Mays James L. Peters Shadow Wood Country Club Neil G. Van Luven Bob McKnight Robert E. Petersen David M. Shaffer Basil K. Vasiliou Sherman R. Miller, IV Pharmaceutical Research and Michael S. Shannon The Daniel Veloric Foundation Casey Nelson Manufacturers of America Carl and Ruth Shapiro Velos Medical Informatics, Inc. Ryan Nelson Philadelphia Insurance Companies Family Foundation Mary E. Venable Joseph Nuzzarello Phillies Charities, Inc. Robert F. Shapiro The Villages Nick O’Kane Cynthia H. Polsky Stephen Shechtma Robert and Judy Waller Rob Parker Gerald Porter Thomas and Madeleine Sherak David E. Walters Ian Parmiter Timothy N. Poster The Shidler Family Foundation John Walton Propane Industry Pros4Care Melvin and Barbara Powell Herbert J. Siegel Jack L. Warner Andy Petranek Rick Powell William Siegel Roger Weber Steve Rakow Ed Prager Adrianne W. Silver Martha Weckel George R. Reinhardt Arlen I. Prentice Richard Silverman Raymond J. Weis Pete Ridge Richard E. Previdi Ronald A. Simms Robert Weiss Will Rutledge Wayne Prim, Sr. David Simon Jay Weitzman Kelly Slater Edward Probyn Dick Simon Wheels, Inc. Karen Smyers Bob Pryt Mimi Simoneaux Miles D. White Neal Thompson John A. Ptak Jonathan and Plum Simons Jeffrey S. Wilks Brett J. Troia William and Melody Purdy James D. Sinegal Kenneth and Nancy Williams Steven Trussell Kjell H. Qvale Van Skilling Gary L. Wilson Team Winter Mark Rachesky Joel E. Smilow Daniel P. Wimsatt Rebecca L. Vozzo Robert E. Racicot Gordon Smith Wolff Family Foundation Jamie Weisman Steve Rader Jeff N. Smith The Liberal Do-Gooder Foundation John M. White Raley’s Gold Rush Classic Arnold Snider Moira Wolofsky Matt Woehnker Max Ramberg Steve Snyder Wolters Kluwer Health John Yodzis Raymond Cristobal Memorial Mr. and Mrs. Stuart M. Solomon Kenneth R. Woods Pam Zam Fund, Inc. James Soules Working Assets Donald Rechler Southern Company Services, Inc. Rodney A. Wray

Scott Gregg Rechler Southern Wine & Spirits of Robert A. Yawitt Joseph P. Riccardo Nevada, Inc. Bud Yorkin Blair & Kristin Richardson Foundation Larry Spitcaufsky Young Presidents Organization Ritz-Carlton Boston Richard and Ellie Sprague Rebel Chapter Ritz-Carlton Chevy Chase The Sprenger Lang Foundation Gary A. Young Lee P. Rizzuto Frank P. Stagen Zenkel Foundation Linda G. Robinson Stak Design, Inc. Stan Zicklin Represents cumulative donations Sam Robson Starbucks Coffee Company as of December 31, 2009.

20 2009-2010 progress report EVENTS FOR CURES Each year, PCF benefits from events that provide an opportunity to communicate PCF’s mission, support awareness for the cause and raise funds for research. These events provide our supporters with a broad range of opportunities to get involved for cures.

Clockwise from top left: PCF’s 2009 New York Dinner, featuring David Foster and Andrea Bocelli, raised more than $4 million for research and eight new Young Investigators • Major League Baseball’s 2010 All-Star 5K and Fun Run featured more than 9,000 participants and raised $50,000 • More Mo’ Bros and Mo’ Sistas are joining the fun each “Movember,” celebrating moustache growth for research. To date, Movember has raised more than $2.5 million for research • PCF’s annual Home Run Challenge brought our message to baseball fans across the country and raised almost $2 million from pledges in 2010

2009-2010 progress report 21 Appeal for support

Dear Friend,

With recent breakthroughs in research, prostate cancer is at an historic turning point and we are closer than ever to eliminating death and suffering from this disease that affects more than 2.5 million American men and their families. This rate of progress would be unsustainable without your ongoing support.

Your investment in the Prostate Cancer Foundation is carefully deployed. Since 1993, virtually every important discovery in the battle against this disease has been stimulated and fast-forwarded by PCF funding or coordination. Moreover, every dollar you contribute to PCF is multiplied 20 to 30 times. Our activities set into motion a ripple that spurs research at government, biopharma and charitable institutions and, in effect, leverages the millions of dollars we raise into billions.

This past September in Washington, D.C., shoulder to shoulder with our partners in the prostate cancer community, we asked our nation’s leaders to rededicate themselves to scientific innovation and achieve freedom from prostate cancer through increased research funding and enhanced support services for men who are diagnosed.

Your continued generosity is still urgently needed so we can continue the momentum we have achieved and realize our ultimate goal—the end of prostate cancer as a lethal disease.

On behalf of patients, families, caregivers and our research scientists around the world, we appreciate your support and ask that you give now so PCF can “turn off the lights” soon.

With deepest gratitude and wishes for good health,

Jonathan W. Simons, MD President and Chief Executive Officer David H. Koch Chair

22 2009-2010 progress report donation opportunities The Prostate Cancer Foundation welcomes gifts of cash, securities, non-cash assets and gifts by will or living trust. We also welcome contributions made in memory, in tribute or in honor of friends or loved ones.

Challenge Awards ($1,000,000+) Donations

PCF supports transformational prostate cancer Please mail your check to: research to accelerate progress toward the Prostate Cancer Foundation reduction of death and suffering due to advanced 1250 Fourth Street prostate cancer. Santa Monica, CA 90401 Teams may be assembled from one or several To make an online contribution, please visit our institutions and should include at least three website: www.pcf.org investigators capable of providing unique scientific expertise to the solution of a significant problem in If you prefer, you can make a donation by phone by prostate cancer research. Ranging from $300,000 calling toll-free (800) 757-CURE (2873). to $1,000,000 per year for three years, these awards will cover direct costs of the research. Memorial or Tribute Gifts • Honor the memory of a loved one or celebrate the Creativity Awards ($300,000) accomplishments of a friend or family member PCF supports innovative and daring research with by helping others Creativity Awards. Paid over a two-year period, these awards totaling $300,000 support exceptionally novel • Make a memorial or tribute gift and PCF will send an acknowledgement card to the family projects with great potential to produce or honoree breakthroughs for detecting and treating prostate cancer. They are complementary and integrated with Monthly Giving other PCF award programs. • Set up recurring donations for a convenient and Young Investigator Awards ($225,000) manageable gift process that fits your monthly budget PCF provides these three-year awards, totaling $225,000, to keep the field of prostate cancer Other Gift Suggestions research vibrant with new ideas. The awards, • Assets or property including appreciated stock matched by recipients’ institutions, offer career and and real estate project support for young but proven investigators (35 years or less) who are committing their lives to a • Bequest – remember PCF in your will cure for prostate cancer. • Name PCF as the primary or contingent beneficiary on a life insurance policy

For more information, visit www.pcf.org/donate

2009-2010 progress report 23 Prostate Cancer Foundation Statements of Financial Position

December 31 2009 2008

Assets

Current assets: Cash and cash equivalents $ 30,510,823 $ 27,894,591 Pledges receivable 6,334,109 4,043,333 Marketable securities 51,968 25,312 Prepaid expenses 58,523 80,497 Other receivables 120,547 – Total current assets 37,075,970 32,043,733 Furniture, equipment and improvements: Furniture and fixtures 37,180 37,180 Office equipment 210,672 110,574 Leasehold improvements 246,891 246,891 Computer software 385,464 344,384 880,207 739,029 Less accumulated depreciation (688,415) (606,244) 191,792 132,785 Investments 560,000 960,000 Long-term pledges receivable 2,086,917 2,772,772 Total assets $ 39,914,679 $ 35,909,290

Liabilities and net assets

Current liabilities: Accounts payable $ 130,614 $ 76,830 Accrued liabilities 309,588 953,057 Accrued payroll and payroll-related liabilities 573,438 424,103 Research awards payable 13,238,378 10,356,378 Total current liabilities 14,252,018 11,810,368

Long-term research awards payable 3,115,000 8,106,377 Total liabilities 17,367,018 19,916,745

Unrestricted net assets 22,547,661 15,992,545 Total liabilities and net assets $ 39,914,679 $ 35,909,290

24 2009-2010 progress report Prostate Cancer Foundation Statements of Activities

December 31 2009 2008

Support and revenues: Donations $ 33,265,074 $ 36,720,708 Net realized and unrealized loss on investments (415,074) (3,805) Interest and other income 329,244 520,254 Total support and revenues 33,179,244 37,237,157 Program services: Research grants, association awards and donations 15,153,848 28,069,538 Scientific conferences 2,059,200 2,086,024 Public awareness and advocacy expense 2,194,062 2,529,047 Total program services 19,407,110 32,684,609

General and administrative expenses 2,714,456 2,887,230 Fund-raising expenses 4,502,562 4,403,510 Total expenditures 26,624,128 39,975,349 Increase (decrease) in net assets 6,555,116 (2,738,192)

Net assets at beginning of year 15,992,545 18,730,737 Net assets at end of year $ 22,547,661 $ 15,992,545

2009-2010 progress report 25 Prostate Cancer Foundation Statements of Cash Flows

December 31 2009 2008

Operating activities Increase (decrease) in net assets $ 6,555,116 $ (2,738,192) Adjustments to reconcile increase (decrease) in net assets to net cash provided by operating activities: Depreciation and amortization 82,171 63,787 Donation of marketable securities (399,533) (116,462) Net realized and unrealized loss on investments 415,074 3,805 Proceeds from sales of marketable securities 384,459 237,758 changes in operating assets and liabilities: Pledges receivable (1,604,921) 862,649 Marketable securities (26,656) (1,057,545) Prepaid expenses 21,974 (21,281) Other receivables (120,547) 50,564 Accounts payable 53,784 (289,705) Accrued liabilities (643,469) (109,955) Accrued payroll and payroll-related liabilities 149,335 (59,745) Research awards payable (2,109,377) 9,812,755 Net cash provided by operating activities 2,757,410 6,638,433 Investing activities Purchase of furniture, equipment and improvements (141,178) (19,104) Net cash used in investing activities (141,178) (19,104)

Net increase in cash and cash equivalents 2,616,232 6,619,329 Cash and cash equivalents at beginning of year 27,894,591 21,275,262 Cash and cash equivalents at end of year $ 30,510,823 $ 27,894,591

26 2009-2010 progress report Prostate Cancer Foundation Report of Independent Auditors

Board of Directors Prostate Cancer Foundation

We have audited the statements of financial position of Prostate Cancer Foundation (the Foundation) as of December 31, 2009 and 2008, and the related statements of activities and cash flows for the years then ended. These financial statements are the responsibility of the Foundation’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States and the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Foundation’s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Foundation at December 31, 2009 and 2008, and the changes in its net assets and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States.

August 27, 2010

2009-2010 progress report 27 PARTNERS FOR PROGRESS PCF is grateful for the support of our Partners for Progress. These organizations’ major contributions and campaigns are enabling PCF to move closer to our goal of realizing a world without prostate cancer.

Platinum Partners

TM

Supporting Partners

TM

Biotechnology & Pharmaceutical Partners

28 2009-2010 progress report BOARD OF DIRECTORS & LEADERSHIP TEAM

Board of Directors Leadership Team Michael Milken Peter T. Grauer Lori Milken Jonathan W. Simons, MD Founder and Chairman Chairman Vice President President and Prostate Cancer Foundation Bloomberg, LP Prostate Cancer Foundation Chief Executive Officer David H. Koch Chair Charles F. Baird, Jr. The Reverend Rosey Grier Jerry Monkarsh Managing Partner The Milken Family Foundation Partner Ralph Finerman North Castle Partners EJM Development Chief Financial Officer, Stuart Holden, MD Treasurer and Secretary J. Darius Bikoff Director, Louis Warschaw Henry L. Nordhoff Founder Prostate Cancer Center Vice Chairman Gary Dicovitsky The Observatory US, Inc. Cedars-Sinai Medical Center The Shipston Group Executive Vice President Development James C. Blair Arthur H. Kern Lynda Resnick General Partner Investor Vice Chairman Howard R. Soule, PhD Domain Associates Roll International Executive Vice President and David H. Koch Chief Science Officer Steven A. Burd Executive Vice President Bert C. Roberts, Jr. Chairman, President and Koch Industries Consultant Stuart Holden, MD Chief Executive Officer BR Ventures Medical Director Safeway, Inc. Richard S. LeFrak Chairman, President and Richard V. Sandler Jan Haber The Honorable Chief Executive Officer Vice President Vice President S. Ward Casscells, MD The LeFrak Organization Maron & Sandler Events, Donor Relations John E. Tyson Distinguished Executive Vice President Professor of Medicine and Public The Honorable Earle I. Mack Milken Family Foundation Helen Hsieh Health, and Vice President for Senior Partner Vice President External Affairs and Public Policy The Mack Company J. Gary Shansby Finance and Administration University of Texas Health Science Chairman Center at Houston Jeffrey A. Marcus Partida Tequila, LLC Dave Perron Managing Director Vice President David A. Ederer Crestview Advisors Lawrence J. Stupski Baseball and Sports Enterprises Chairman Chairman Ederer Investment Company Shmuel Meitar Stupski Foundation Jan Wolterstorff Director Vice President David J. Epstein Aurec Group Stanley R. Zax Movember Initiatives Founder President and Chairman ACS Clearinghouse Leslie D. Michelson Zenith National Insurance Corp. Dan Zenka, APR Chief Executive Officer Vice President R. Christian B. Evensen Private Health Management Communications Managing Partner Flintridge Capital EJ Milken Investments, LLC Co-Founder Milken Institute Young Leaders’ Circle

PCF’s research and outreach progress provides an important base for accelerating the end of suffering from prostate cancer. pcf.org

Cert no. SCS-COC-001345 1250 Fourth Street, Santa Monica, CA 90401 Tel 800.757.CURE (2873) Fax 310.570.4701